Key takeaways There is no proven “testosterone diet.” The strongest evidence is that correcting a documented nutrient deficiency (such as zinc) may help, while supplementing men who already have adequate intake generally does not. Vitamin D supplementation did not meaningfully raise testosterone in randomized trials, even in vitamin D-insufficient men, so popular “vitamin D foods […]
Key takeaways Yes, testosterone is a federally controlled substance: it sits in DEA Schedule III, placed there by Congress through the Anabolic Steroid Control Acts of 1990 and 2004. Because it is a Schedule III drug, testosterone requires a valid prescription, and under 21 CFR 1306.22 a script cannot be filled or refilled more than […]
Key takeaways The cost of TRT is driven by three things: the modality (injections are typically the least expensive; gels are higher; pellets are highest because of an insertion fee), the required diagnostic workup and ongoing monitoring, and whether you pay cash or use insurance. Across the general US cash-pay market, published figures range from […]
Key takeaways Whether TRT is covered by insurance is plan-specific: coverage is generally more likely when there is a properly documented clinical diagnosis of hypogonadism, and you should always verify benefits, prior-authorization rules, and formulary status with your own plan. Major commercial payers commonly require prior authorization plus documentation of persistent symptoms and two low […]
Key takeaways Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that works upstream on the brain rather than supplying testosterone directly. It is not FDA-approved for any use; in the US it is available only as a compounded, prescription-only drug used off-label in men, and the FDA has not evaluated […]
Key takeaways In a systematic review of hypogonadal men, effects of testosterone treatment on sexual interest typically began around 3 weeks and plateaued near 6 weeks, while fuller effects on spontaneous erections could take up to 6 months (Saad et al., European Journal of Endocrinology, 2011). Different outcomes move on different clocks: mood changes often […]
Key takeaways Low desire is the most common female sexual complaint, but it is only diagnosed as hypoactive sexual desire disorder (HSDD) when it causes marked personal distress — reported in the PRESIDE survey in roughly 8.9% of women at ages 18–44, 12.3% at 45–64, and 7.4% at 65 and older. There is no FDA-approved […]
Key takeaways Sermorelin is a growth hormone secretagogue, not HGH: it prompts your own pituitary to release growth hormone in natural pulses rather than supplying the hormone from outside. Robust, modern human trials of sermorelin for sleep, recovery, or body composition in healthy aging adults are lacking; its strongest evidence is decades-old data in growth-hormone-deficient […]
Key takeaways On the historical FDA label for sermorelin acetate (Geref), the most common treatment-related side effect was a local injection-site reaction (pain, swelling, or redness), reported in about 1 patient in 6. All sermorelin available in the United States in 2026 is compounded under sections 503A/503B. Compounded sermorelin is not FDA-approved and has not […]
Key takeaways Sermorelin is given by subcutaneous injection. In its FDA-approved pediatric history and pivotal trial it was dosed once daily, and the studied timing was at bedtime, but that figure was a pediatric study dose and is reference-only, not a recommendation for adult wellness use. The bedtime-dosing rationale is often described as aligning with […]
